Bruno Silva

Bruno Silva

Auto-generated profile, based on publicly available information

Bruno Silva

Instituto de Medicina Molecular João Lobo Antunes (iMM), Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
BSBruno Silva
Bruno Silva
PFPaula Faustino
Paula Faustino

28 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBruno Silva
Bruno Silva
RPRichard Pentz
Richard Pentz
AFAna Margarida Figueira
Ana Margarida Figueira
RARajika Arora
Rajika Arora
YLYong Woo Lee
Yong Woo Lee
CAClaus Azzalin
Claus Azzalin
Telomerase negative immortal cancer cells elongate telomeres through the Alternative Lengthening of Telomeres (ALT) pathway. While sustained telomeric replicative stress is required to maintain ALT, it might also lead to cell death when excessive. Here, we show that the ATPase/translocase activity of FANCM keeps telomeric replicative stress in check specifically in ALT cells. When FANCM is depleted in ALT cells, telomeres become dysfunctional, and cells stop proliferating and die. FANCM depletion also increases ALT-associated marks and de novo synthesis of telomeric DNA. Depletion of the BLM helicase reduces the telomeric replication stress and cell proliferation defects induced by FANCM inactivation. Finally, FANCM unwinds telomeric R-loops in vitro and suppresses their accumulation in cells. Overexpression of RNaseH1 completely abolishes the replication stress remaining in cells codepleted for FANCM and BLM. Thus, FANCM allows controlled ALT activity and ALT cell proliferation by limiting the toxicity of uncontrolled BLM and telomeric R-loops.

18 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBruno Silva
Bruno Silva
RARajika Arora
Rajika Arora
SBSilvia Bione
Silvia Bione
CAClaus Azzalin
Claus Azzalin
Alternative Lengthening of Telomeres (ALT) is a Break-Induced Replication (BIR)-based mechanism elongating telomeres in a subset of human cancer cells. While the notion that spontaneous DNA damage at telomeres is required to initiate ALT, the molecular triggers of this physiological telomere instability are largely unknown. We previously proposed that the telomeric long noncoding RNA TERRA may represent one such trigger; however, given the lack of tools to suppress TERRA transcription in cells, our hypothesis remained speculative. We have developed Transcription Activator-Like Effectors able to rapidly inhibit TERRA transcription from multiple chromosome ends in an ALT cell line. TERRA transcription inhibition decreases marks of DNA replication stress and DNA damage at telomeres and impairs ALT activity and telomere length maintenance. We conclude that TERRA transcription actively destabilizes telomere integrity in ALT cells, thereby triggering BIR and promoting telomere elongation. Our data point to TERRA transcription manipulation as a potentially useful target for therapy.

1 April 2014 in Neurobiology of Aging
Verified
Journal Article
Closed access
ÂCÂngela C. Crespo
Ângela C. Crespo
BSBruno Silva
Bruno Silva
LMLiliana Marques
Liliana Marques
EMErica Marcelino
Erica Marcelino
CMCarolina Maruta
Carolina Maruta
MMMadalena Martins
Madalena Martins

1 February 2012 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
LMLiliana Marques
Liliana Marques
AAAnne Auriac
Anne Auriac
AWAlexandra Willemetz
Alexandra Willemetz
JBJoão Banha
João Banha
BSBruno Silva
Bruno Silva
LCLuciana Costa
Luciana Costa

3 March 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RMRute Martins
Rute Martins
BSBruno Silva
Bruno Silva
DPDaniela Proença
Daniela Proença
PFPaula Faustino
Paula Faustino
The pathophysiology of HFE-derived Hereditary Hemochromatosis and the function of HFE protein in iron homeostasis remain uncertain. Also, the role of alternative splicing in HFE gene expression regulation and the possible function of the corresponding protein isoforms are still unknown. The aim of this study was to gain insights into the physiological significance of these alternative HFE variants. Alternatively spliced HFE transcripts in diverse human tissues were identified by RT-PCR, cloning and sequencing. Total HFE transcripts, as well as two alternative splicing transcripts were quantified using a real-time PCR methodology. Intracellular localization, trafficking and protein association of GFP-tagged HFE protein variants were analysed in transiently transfected HepG2 cells by immunoprecipitation and immunofluorescence assays. Alternatively spliced HFE transcripts present both level- and tissue-specificity. Concerning the exon 2 skipping and intron 4 inclusion transcripts, the liver presents the lowest relative level, while duodenum presents one of the highest amounts. The protein resulting from exon 2 skipping transcript is unable to associate with β2M and TfR1 and reveals an ER retention. Conversely, the intron 4 inclusion transcript gives rise to a truncated, soluble protein (sHFE) that is mostly secreted by cells to the medium in association with β2M. HFE gene post-transcriptional regulation is clearly affected by a tissue-dependent alternative splicing mechanism. Among the corresponding proteins, a sHFE isoform stands out, which upon being secreted into the bloodstream, may act in remote tissues. It could be either an agonist or antagonist of the full length HFE, through hepcidin expression regulation in the liver or by controlling dietary iron absorption in the duodenum.